Navigation Links
Study Finds Exergen Temporal Artery Thermometry Accurate on Newborns
Date:4/18/2011

WATERTOWN, Mass., April 18, 2011 /PRNewswire/ -- Measuring the body temperatures of newborns with temporal artery thermometry (forehead scanning) provides readings comparable to results obtained by axillary (under arm) thermometry, the clinically recommended method for this patient population, but causes less discomfort, according to a new study reported in Advances in Neonatal Care.  

The study(1), the first published clinical analysis evaluating the accuracy of temporal artery thermometry in neonates, compared the accuracy of temporal artery and axillary temperature readings as well as the discomfort level of newborns while obtaining the temperature readings. The sample included stable, mostly normothermic newborns with a gestational age between 32 and 40 weeks at birth hospitalized in a neonatal intensive care unit (NICU).  Rectal thermometry was used as the reference.

Researchers noted that axillary temperatures measured with an electronic thermometer probe are difficult to obtain without disturbing newborns, such disturbances causing increased respiratory and heart rates and lower oxygen saturation.  During the study, measurements taken using temporal artery thermometry resulted in a statistically significant improvement in comfort scores.  

An excerpt from the published study confirms this: "Neonates experienced less discomfort with the temporal artery thermometer than with the axillary thermometer method."  In addition, the authors stated: "The statistical equivalency of the temporal artery and axillary temperatures, coupled with less discomfort to the neonate during temporal artery device use, makes the temporal artery thermometer an attractive alternative for temperature monitoring in neonates."

"This independent research validates our findings about the usefulness of temporal artery thermometry," said Francesco Pompei, Ph.D., CEO of Exergen Corp. "Exergen's patented TemporalScanner™ Thermometer was developed in response to healthcare providers' and caregivers' at home need for a gentle, noninvasive, and accurate method of thermometry for all ages, from newborns to geriatrics."

The clinical research, which used an infra-red electronic temperature device made by Exergen Corp., was conducted at a level IIIa NICU in a not-for-profit hospital in the Western United States. It showed body temperature readings taken at the temporal artery and the clinically recommended under the arm method were similarly accurate when compared to rectal thermometry. The amount of deviation from the reference readings was within the standard set for noninvasive temperature measurement.

The study was not affiliated with Exergen and neither the authors nor the institution received compensation from the company to conduct the research.

Exergen markets two models of the TemporalScanner thermometer: a professional version for doctors' offices and hospitals, and a consumer model sold in major retailers including Wal-Mart, Target, Walgreen's, Costco, Sam's Club, Babies "R" Us, Toys "R" Us, and BJ's. More than 800 million temperatures are taken each year with the TemporalScanner. Used in thousands of hospitals, clinics, and pediatricians' offices in the country as well as in millions of homes, it is also the only thermometer manufactured in the United States.  

Exergen Corporation is recognized worldwide as an innovator and leading manufacturer of patented infrared thermometers, scanners, sensors and controls. The company holds more than 60 U.S. patents for non-invasive temperature measurement devices. Its products are used in a wide variety of industrial and medical applications for both professionals and consumers. For additional information, visit www.exergen.com.

(1) Gail Lee, RN, et al; Accuracy of Temporal Artery Thermometry in Neonatal Intensive Care Infants, in Advances in Neonatal Care,  Vol. 11, No. 1, pp 62-70.


'/>"/>
SOURCE Exergen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Finds Letter to Health Care Providers Results in Reduction of Potentially Unsafe Concurrent Use of Plavix and Proton Pump Inhibitors
2. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
3. Adeonas Clinical Study of reaZin™ Meets Primary Outcomes of Increasing Serum Zinc and Decreasing Serum Free Copper
4. Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting
5. Analytical Bio-Chemistry (ABC) Laboratories Implements eStudy™ Hosted Platform to Support its Ecotoxicology and Other Service Offerings
6. Marinus Pharmaceuticals Announces U.S. Department of Defense Grant to Study Ganaxolone in Fragile-X Syndrome
7. Max Neeman International Completes Targeted Enrollment of 15,000 for Large Ph IV Study
8. DURECT Announces ELADUR® (TRANSDUR®-Bupivacaine) Phase II Study Results in Chronic Low Back Pain
9. New Published Study Finds Masimo SET® Delivers More Reliable Measurements Significantly Faster Than Other Pulse Oximetry Technologies
10. Vanda Pharmaceuticals Announces Commencement of Clinical Study of Long-Acting Injectable Formulation of Fanapt®
11. Study Highlights Successes of Ascension Health Quality Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  Syneron Medical Ltd. ... device company, announced today that William Griffing ... America, is scheduled to participate in the Leerink ... on February 11, 2016 in New ... institutional investors to meet with the Mr. Griffing ...
(Date:2/5/2016)... 5, 2016 ... the "Global Musculoskeletal Partnering 2010-2016: Deal ... to their offering. --> ... the "Global Musculoskeletal Partnering 2010-2016: Deal ... to their offering. --> ...
(Date:2/5/2016)... , Feb. 5, 2016  Zimmer Biomet Holdings, ... of the previously announced underwritten secondary offering of 11,027,558 ... stockholders, consisting of affiliates of Blackstone and Goldman Sachs. ... an initial price of $96.45 per share. The selling ... offering.  Neither Zimmer Biomet nor any of its directors, ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... Brenntag Specialties, Inc.(BSI) , ... Food & Beverage and Dietary Supplement market segments across the ... USA geographies east of the Rocky Mountains since 2012. Consistent performance in ...
(Date:2/8/2016)... ... February 08, 2016 , ... ... LA, celebrates the beginning of a new charity campaign. As part of their ... Special Advocates (CASA). In the belief that children deserve a voice, and in ...
(Date:2/8/2016)... ... 2016 , ... A man who has struggled to quit smoking, a man who has struggled ... to find solutions to his problems – and he did. Now Nabat, a serial entrepreneur ... introduce his breakthrough inventions to the world and better people's lives. His own experience with ...
(Date:2/8/2016)... ... ... If you are feeling that your clothes are a tad snug, the ... Center for Disease Control and Prevention (CDC), 34.9% of U.S. adult women are overweight. ... some of the leading causes of preventable death. February is heart health month ...
(Date:2/8/2016)... Hilton Head Island, SC (PRWEB) , ... February 08, 2016 , ... ... Head and surrounding areas with a vital new community enrichment program, has teamed up ... to local women and children suffering from intimate abuse. To support all those victimized ...
Breaking Medicine News(10 mins):